Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe
Authors: L. Stranix-Chibanda
S. Brummel
J. Pilotto
M. Mutambanengwe
V. Chanaiwa
T. Mhembere
M. Kamateeka
J. Aizire
G. Masheto
R. Chamanga
M. Maluwa
S. Hanley
E. Joao
G. Theron
N. Nevrekar
M. Nyati
B. Santos
L. Aurpibul
M. Mubiana-Mbewe
R. Oliveira
T. Anekthananon
P. Mlay
K. Angelidou
C. Tierney
L. Ziemba
A. Coletti
K. McCarthy
M. Basar
N. Chakhtoura
R. Browning
J. Currier
M. G. Fowler
P. Flynn
FHI 360
Botswana Harvard AIDS Institute Partnership
Centre for the AIDS Programme of Research in South Africa
Frontier Science & Technology Research Foundation, Inc.
Centre for Infectious Disease Research in Zambia
UNC Project-Malawi
University of Malawi College of Medicine
Makerere University
Kilimanjaro Christian Medical Centre
Hospital Nossa Senhora da Conceicao
Hospital Geral de Rio de Janeiro
University of Zimbabwe
University of California, Los Angeles
St. Jude Children's Research Hospital
National Institute of Child Health and Human Development
National Institute of Allergy and Infectious Diseases
Faculty of Medicine, Siriraj Hospital, Mahidol University
Center for Biostatistics in AIDS Research
Universiteit Stellenbosch
Johns Hopkins School of Medicine
Universidade Federal do Rio de Janeiro
BJ Government Medical College
Hospital Federal dos Servidores do Estado
Chiang Mai University
Perinatal HIV Research Unit
Keywords: Medicine
Issue Date: 1-Sep-2019
Citation: AIDS and Behavior. Vol.23, No.9 (2019), 2522-2531
Abstract: © 2019, The Author(s). The PROMISE trial enrolled asymptomatic HIV-infected pregnant and postpartum women not eligible for antiretroviral treatment (ART) per local guidelines and randomly assigned proven antiretroviral strategies to assess relative efficacy for perinatal prevention plus maternal/infant safety and maternal health. The START study subsequently demonstrated clear benefit in initiating ART regardless of CD4 count. Active PROMISE participants were informed of results and women not receiving ART were strongly recommended to immediately initiate treatment to optimize their own health. We recorded their decision and the primary reason given for accepting or rejecting the universal ART offer after receiving the START information. One-third of participants did not initiate ART after the initial session, wanting more time to consider. Six sessions were required to attain 95% uptake. The slow uptake of universal ART highlights the need to prepare individuals and sensitize communities regarding the personal and population benefits of the “Treat All” strategy.
ISSN: 15733254
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.